PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML
Sophie Park(Centre National de la Recherche Scientifique), Didier Bouscary(Centre National de la Recherche Scientifique), Zachary A. Knight(Howard Hughes Medical Institute), Patrick Mayeux(Université Paris Cité), Nabih Azar(Assistance Publique – Hôpitaux de Paris), Norbert Ifrah(Inserm), Nathalie Gallay(Inserm), Nicolas Chapuis(Délégation Paris 5), Valérie Bardet(Délégation Paris 5), Kevan M. Shokat(Howard Hughes Medical Institute), F Viguié(Délégation Paris 5), François Dreyfus(Université Paris-Sud), Jérôme Tamburini(University of Geneva), C. Lacombe(Délégation Paris 5), Lise Willems(Centre National de la Recherche Scientifique)
Cited by 193
Related Papers
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
|New England Journal of Medicine|2002|1.2k
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
|PLoS Biology|2009|1.1k
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia
|Journal of Clinical Oncology|2013|543